5Arend O, Harris A, Wolter P, et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients[J]. Acta Ophthalmol Scand,2003,81(5): 474.
6Kaluzny JJ, Szaflik J, Czechowicz-Janicka K, et al. Timolol0.5% / dorzolamide 2 % fixed combination versus timolol 0.5%/pilocarpine 2 % fixed combination in primary openangle glaucoma or ocular hypertensive patients [J].Acta Ophthalmol Scand, 2003,81 (4):
7Nesher R, Ticho U. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide:effect on the quality of life of glaucoma patients with drug-related side effects[J]. Isr Med Assoc J, 2003,5(4): 260.
8Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonicanhydrase in hibitor for primary open-angle glaucoma and ocular hypertension[J]. Am J Ophthalmol, 1998, 126(3): 400.
9Sodhi PK, Pandey RM, Ratan SK. Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma [J]. Int J Clin Pract, 2003 , 57(10): 875.
10Orzalesi N. Effect oftimolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension [J].Invest Ophthalmol Vis Sci, 2000, 41(9):2566.
